Explore our collection of educational resources, publications, and more

Filter by:

PGDx Corporate, Product, and Service Offering Overviews

Publication Executive Summaries

Virtual Event Summaries

Conference Posters

Corporate and Lab Documentation


See how PGDx elio Solutions
can inform research

Researchers all around the world are using PGDx elio tissue complete. Here are some of the breakthroughs that have been made possible.

FIDES trials with Basilea

Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02).

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03).

KEYNOTE-495 with Merck

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475 – 495/KEYNOTE-495).

MRD trial with NKI

Prevention of recurrent disease by additional chemotherapy in patients with detectable circulating tumor DNA in the blood after surgery for stage II (lymph nodes unaffected) colon cancer.

Log in to access more information